TerminatedPhase 2NCT02664961
Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)
Studying Epithelioid trophoblastic tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Tracon Pharmaceuticals Inc.
- Principal Investigator
- Charles Theuer, MD, PhD, MDTracon Pharmaceuticals Inc.
- Intervention
- TRC105(drug)
- Enrollment
- 3 enrolled
- Eligibility
- 16-99 years · FEMALE
- Timeline
- 2016 – 2018
Study locations (3)
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Ohio State University, Columbus, Ohio, United States
- UT Southwestern, Dallas, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02664961 on ClinicalTrials.gov